Table 1

Patient characteristics of new-user DPP-4i cohort before and after propensity score matching

DPP-4i new user cohort before propensity score matchingDPP-4i new user cohort after propensity score matching
DPP-4i
(n=6206)
SU
(n=22 128)
DPP-4i
(n=6008)
SU
(n=6008)
Age in years (SD)58 (12.2)60.5 (13.8)58.1 (12.2)58.2 (12.5)
Female2258 (36.4%)8107 (36.6%)2189 (36.4%)2187 (36.4%)
Measure of deprivation
 Least624 (10.1%)2492 (11.3%)603 (10%)594 (9.9%)
 Most615 (9.9%)2342 (10.6%)603 (10%)614 (10.2%)
 Unknown2862 (46.1%)8780 (39.7%)2739 (45.6%)2683 (44.7%)
Diabetes duration in years (SD)2.0 (1.8)1.0 (1.5)1.9 (1.7)1.9 (1.8)
Body mass index >304162 (67.1%)10 661 (48.2%)3994 (66.5%)3978 (66.2%)
No of hospitalisations in year prior to cohort entry
 05647 (91%)18 516 (83.7%)5452 (90.7%)5470 (91%)
 1378 (6.1%)2105 (9.5%)375 (6.2%)379 (6.3%)
 2109 (1.8%)784 (3.5%)109 (1.8%)92 (1.5%)
 3+72 (1.2%)723 (3.3%)72 (1.2%)67 (1.1%)
No of drugs in year prior to cohort entry
 0–4721 (11.6%)3098 (14%)703 (11.7%)671 (11.2%)
 5–103204 (51.6%)10 379 (46.9%)3081 (51.3%)3119 (51.9%)
 11+2281 (36.8%)8651 (39.1%)2224 (37%)2218 (36.9%)
HbA1c
<6.5%242 (3.9%)1393 (6.3%)238 (4%)233 (3.9%)
 6.5%–7.5%1104 (17.8%)3349 (15.1%)1049 (17.5%)1053 (17.5%)
 7.5%–9%2831 (45.6%)7121 (32.2%)2701 (45%)2694 (44.8%)
 9%+2000 (32.2%)9833 (44.4%)1991 (33.1%)2007 (33.4%)
 Unknown29(<1%)432 (2%)29(<1%)21(<1%)
eGFR <60883 (14.2%)4429 (20%)857 (14.3%)890 (14.8%)
Diagnoses in year prior to cohort entry
 Heart failure68 (1.1%)369 (1.7%)68 (1.1%)51(<1%)
 Hypertension1095 (17.6%)4475 (20.2%)1066 (17.7%)1087 (18.1%)
 Dyslipidaemia213 (3.4%)1093 (4.9%)213 (3.5%)212 (3.5%)
 Ischaemic heart disease174 (2.8%)1033 (4.7%)171 (2.8%)168 (2.8%)
 Peripheral vascular disease25(<1%)145(<1%)25(<1%)24(<1%)
Prescription drug use in year prior to cohort entry
 Metformin5775 (93.1%)16 534 (74.7%)5578 (92.8%)5638 (93.8%)
 AcarboseS8(<1%)SS
 SGLT2 inhibitors38(<1%)93(<1%)38(<1%)40(<1%)
 Meglitinide47(<1%)39(<1%)38(<1%)29(<1%)
 Thiazolidinedione252 (4.1%)403 (1.8%)222 (3.7%)209 (3.5%)
 Insulin82 (1.3%)331 (1.5%)80 (1.3%)86 (1.4%)
 Hypnotic332 (5.3%)1486 (6.7%)328 (5.5%)324 (5.4%)
 Mood85 (1.4%)280 (1.3%)81 (1.3%)83 (1.4%)
 Anticonvulsant271 (4.4%)832 (3.8%)260 (4.3%)266 (4.4%)
 Antipsychotics176 (2.8%)829 (3.7%)172 (2.9%)171 (2.8%)
  • S, suppressed due to low number of events.

  • DPP-4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin A1c; SGLT2, sodium-dependent glucose cotransporter-2; SU, sulfonylureas.